Is Amazon an AI Stock?
With the market starting to look skittish on pure-play AI…
Sell
28
RCKT Quote, Financials, Valuation and Earnings
Last price:
$3.43
Seasonality move
:
4.26%
Day range:
$3.32 - $3.46
52-week range:
$2.19 - $15.00
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
--
P/B ratio:
1.18x
Volume:
1.1M
Avg. volume:
1.9M
1-year change:
-74.82%
Market cap:
$370.1M
Revenue:
--
EPS (TTM):
-$2.25
Analysts' Opinion
-
Consensus RatingRocket Pharmaceuticals, Inc. has received a consensus rating of Buy. The company's average rating is a Buy based on 7 Buy ratings, 5 Hold ratings, and 1 Sell rating.
-
Price Target UpsideAccording to analysts' consensus price target of $7.95, Rocket Pharmaceuticals, Inc. has an estimated upside of 132.59% from its current price of $3.42.
-
Price Target DownsideAccording to analysts, the lowest downside price target is $2.00 representing 100% downside risk from its current price of $3.42.
Fair Value
-
According to the consensus of 13 analysts, Rocket Pharmaceuticals, Inc. has 132.59% upside to fair value with a price target of $7.95 per share.
RCKT vs. S&P 500
-
Over the past 5 trading days, Rocket Pharmaceuticals, Inc. has overperformed the S&P 500 by 3.83% suggesting its relative strength compared to the major market average is strong at this time.
Share Buyback
-
Rocket Pharmaceuticals, Inc. does have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
Rocket Pharmaceuticals, Inc. has grown year-over-year revenues for 0 quarters straight. In the most recent quarter Rocket Pharmaceuticals, Inc. reported revenues of --.
Earnings Growth
-
Rocket Pharmaceuticals, Inc. has grown year-over-year earnings for 10 quarters straight. In the most recent quarter Rocket Pharmaceuticals, Inc. reported earnings per share of -$0.45.
Enterprise value:
172.4M
EV / Invested capital:
0.51x
Price / LTM sales:
--
EV / EBIT:
--
EV / Revenue:
--
PEG ratio (5yr expected):
--
EV / Free cash flow:
-0.85x
Price / Operating cash flow:
--
Enterprise value / EBITDA:
--
Gross Profit (TTM):
-$11.1M
Return On Assets:
-55.22%
Net Income Margin (TTM):
--
Return On Equity:
-64.31%
Return On Invested Capital:
-60.24%
Operating Margin:
--
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-09-30 | 2024-09-30 | 2025-09-30 | 2024-09-30 | 2025-09-30 | |
| Income Statement | ||||||
| Revenue | -- | -- | -- | -- | -- | |
| Gross Profit | -$6.9M | -$9.3M | -$11.1M | -$2.4M | -$3.2M | |
| Operating Income | -$265.5M | -$273.8M | -$247.2M | -$69.4M | -$52.4M | |
| EBITDA | -$258.5M | -$264.4M | -$236.1M | -$67M | -$49.2M | |
| Diluted EPS | -$3.22 | -$2.75 | -$2.25 | -$0.71 | -$0.45 | |
| Period Ending | 2021-09-30 | 2022-09-30 | 2023-09-30 | 2024-09-30 | 2025-09-30 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | $425.1M | $311.1M | $446.9M | $241.8M | $227.7M | |
| Total Assets | $530.2M | $417.3M | $598.8M | $393.7M | $368M | |
| Current Liabilities | $24.5M | $30.2M | $33.5M | $40M | $31.2M | |
| Total Liabilities | $44.6M | $50M | $57.7M | $63.9M | $54.4M | |
| Total Equity | $485.7M | $367.3M | $541.1M | $329.8M | $313.7M | |
| Total Debt | $22.5M | $21.5M | $24.1M | $24.6M | $24M | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-09-30 | 2024-09-30 | 2025-09-30 | 2024-09-30 | 2025-09-30 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | -$221.7M | -$192.2M | -$202.2M | -$52.1M | -$50.4M | |
| Cash From Investing | -$65.8M | $28.8M | $29.5M | $78.9M | $93.6M | |
| Cash From Financing | $316.6M | $3.4M | $183M | $200K | -$59K | |
| Free Cash Flow | -$236.8M | -$202.4M | -$202.8M | -$53.7M | -$50.4M | |
RCKT
Sector
Market Cap
$370.1M
$28.4M
Price % of 52-Week High
22.8%
50.35%
Dividend Yield
0%
0%
Shareholder Yield
-51.79%
-1.32%
1-Year Price Total Return
-74.82%
-22.19%
Beta (5-Year)
0.656
0.521
Dividend yield:
0%
Annualized payout:
$0.00
Payout ratio:
--
Growth streak:
0 years
Technicals
8-day SMA
Buy
Level
$3.23
200-day SMA
Sell
Level
$4.61
Bollinger Bands (100)
Buy
Level
2.99 - 3.61
Chaikin Money Flow
Sell
Level
-9.9M
20-day SMA
Buy
Level
$3.14
Relative Strength Index (RSI14)
Buy
Level
54.99
ADX Line
Buy
Level
19.99
Williams %R
Sell
Level
-6.1538
50-day SMA
Buy
Level
$3.41
MACD (12, 26)
Buy
Level
0.05
25-day Aroon Oscillator
Sell
Level
-56
On Balance Volume
Sell
Level
-18.4M
Financial Scores
Buy
Altman Z-Score
(Annual)
Level (8.2815)
Sell
CA Score
(Annual)
Level (-1.0019)
--
Beneish M-Score
(Annual)
Level (--)
Sell
Momentum Score
Level (1)
Sell
Ohlson Score
Level (5.9115)
--
Piotroski F Score
(Annual)
Level (--)
Sell
Quality Ratio Score
Level (1)
Sell
Fundamental Score
Level (2)
Revenue Forecast
Earnings per Share Forecast
Company Profile
Rocket Pharmaceuticals, Inc. is a clinical-stage biotechnology company, which engages in the development of gene therapy treatment options for rare and devastating pediatric diseases. Its multi-platform development approach applies the lentiviral vector and adeno-associated viral vector gene therapy platforms. Its clinical program is an LVV-based gene therapy for the treatment of Fanconi Anemia (FA), a difficult to treat genetic disease that leads to bone marrow failure and potentially cancer. The company was founded on July 7, 1999 and is headquartered in Cranbury, NJ.
Stock Forecast FAQ
In the current month, RCKT has received 7 Buy ratings 5 Hold ratings, and 1 Sell ratings. The RCKT average analyst price target in the past 3 months is $7.95.
-
Where Will Rocket Pharmaceuticals, Inc. Stock Be In 1 Year?
According to analysts, the consensus estimate is that Rocket Pharmaceuticals, Inc. share price will rise to $7.95 per share over the next 12 months.
-
What Do Analysts Say About Rocket Pharmaceuticals, Inc.?
Analysts are divided on their view about Rocket Pharmaceuticals, Inc. share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that Rocket Pharmaceuticals, Inc. is a Sell and believe this share price will drop from its current level to $2.00.
-
What Is Rocket Pharmaceuticals, Inc.'s Price Target?
The price target for Rocket Pharmaceuticals, Inc. over the next 1-year time period is forecast to be $7.95 according to 13 Wall Street analysts, 7 of them rate the stock a Buy, 1 rates the stock a Sell, and 5 analysts rate the stock a Hold.
-
Is RCKT A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for Rocket Pharmaceuticals, Inc. is a Buy. 7 of 13 analysts rate the stock a Buy at this time.
-
How Can I Buy Shares Of RCKT?
You can purchase shares of Rocket Pharmaceuticals, Inc. via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase Rocket Pharmaceuticals, Inc. shares.
-
What Is The Rocket Pharmaceuticals, Inc. Share Price Today?
Rocket Pharmaceuticals, Inc. was last trading at $3.43 per share. This represents the most recent stock quote for Rocket Pharmaceuticals, Inc.. Yesterday, Rocket Pharmaceuticals, Inc. closed at $3.42 per share.
-
How To Buy Rocket Pharmaceuticals, Inc. Stock Online?
In order to purchase Rocket Pharmaceuticals, Inc. stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
Get RCKT Stock Alert
Signup to receive the latest stock alerts
Financial Ratios
RCKT
Sector
P/E ratio
--
23.66x
PEG ratio
--
-0.01x
P/B ratio
1.18x
1.84x
Price / LTM sales
--
1.60x
Growth Metrics
RCKT
Sector
Revenue growth
--
4.85%
Earnings growth
36.34%
11.15%
Revenue (5-year growth)
--
6.45%
Earnings forecast
-$0.52
-$0.20
Profitability
RCKT
Sector
Profitability FY 2024
-$9.4M
$3.6M
Return on invested capital
-60.24%
-30.98%
Return on assets
-55.22%
-27.62%
Return on equity
-64.31%
-36.69%
Earnings Date
Last Earnings Date
Nov
6
Next Earnings Date
Feb
26
Estimated Next Earnings Date
Feb
5
Balance Sheet
RCKT
Sector
Total cash
$222.8M
$27.2M
Short term investments
$208.7M
$25.7M
Total assets
$527.7M
$79.9M
Long term debt
$24M
$4.1M
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Google Vs NVIDIA Stock: Which Is Best?
Alphabet (NASDAQ:GOOGL) and NVIDIA (NASDAQ:NVIDIA) are two of the market’s…
How High Could NVIDIA Stock Go?
NVIDIA (NASDAQ:NVDA) has been one of the best stocks to…
Stock Ideas
Buy
52
Is NVDA Stock a Buy?
Market Cap: $4.5T
P/E Ratio: 62x
Buy
61
Is AAPL Stock a Buy?
Market Cap: $4.1T
P/E Ratio: 38x
Buy
63
Is GOOG Stock a Buy?
Market Cap: $3.8T
P/E Ratio: 40x
Alerts
Sell
44
PSTG alert for Dec 5
Pure Storage, Inc. [PSTG] is up 5.05% over the past day.
Sell
15
HOV alert for Dec 5
Hovnanian Enterprises, Inc. [HOV] is down 22.58% over the past day.
Buy
69
ASTS alert for Dec 5
AST Spacemobile, Inc. [ASTS] is up 18.25% over the past day.
THE #1 STOCK ANALYSIS TOOL
TO MAKE SMARTER BUY AND SELL DECISIONS
Show me the best stock
